Acclaimed Medical Center Appears to Bury Data Undermining COVID-Heart Risk Study

COVID Vaccine

With federal authorities recognizing the plunge in COVID-19 vaccine effectiveness as early as four months after each jab, which may actually increase the risk of subsequent infection, the public health establishment is trying to rekindle Americans’ interest in a so-called layered mitigation strategy to keep COVID infections at bay.

While it leans into one-size-fits-all vaccination as the best way to avoid severe outcomes from an increasingly mild virus with near-total natural immunity nationwide, the Centers for Disease Control and Prevention still recommends wearing any kind of mask and social distancing as an “additional prevention strategy.” 

Read More

Commentary: Moderna Came Up with a Vaccine Against Vaccine Dissent

Moderna Vaccine

Finances at the vaccine manufacturer Moderna began to fall almost as quickly as they had risen, as most Americans resisted getting yet another COVID booster shot. The pharmaceutical company, whose pioneering mRNA vaccine had turned it from small startup to biotech giant worth more than $100 billion in just a few years, reported a third-quarter loss last year of $3.6 billion, as most Americans refused to get another COVID booster shot.

In a September call aimed at shoring up investors, Moderna’s then-chief commercial officer, Arpa Garay, attributed some of the hesitancy pummeling Moderna’s numbers to uninformed vaccine skeptics. “Despite some misinformation,” Garay said, COVID-19 still drove significant hospitalizations. “It really is a vaccine that’s relevant across all age groups,” she insisted.

Read More